Evelo Biosciences Says Co. & Jameel Health Entered Strategic Collaboration
April 26, 2021 | Source: Reuters
Reuters-logo
Reuters reports that Evelo Biosciences and Jameel Health have entered a strategic collaboration to develop and commercialize Evelo’s novel therapy EDP1815 for inflammatory diseases and COVID-19 in select developing markets serving 1.7 billion people.
Read the full article in its original location here.
Related Articles
Arab Health: Early screening 'best weapon' in fight against cancer
An article by The National magazine highlights the latest healthcare technologies presented by Abdul Latif Jameel Health at Arab Health 2023.
Read more
Healthtech provider targets early cancer detection across MENA
Arabian Gulf Business Insight had a conversation with Dr. Akram Bouchenaki, CEO of Abdul Latif Jameel Health, discussing the company's presence in the Global South and the cutting-edge technology it brings to the region.
Read more
One-stop shop helping revolutionize Mideast’s healthcare sector
Arab News engaged in a discussion with Dr. Akram Bouchenaki, CEO of Abdul Latif Jameel Health, to explore the ways in which the company is fulfilling its mission to accelerate modern innovation and deliver advanced healthcare solutions to individuals who might otherwise lack access to them.
Read more
Podcast looks to the future of innovation in the global health sector
Latest Healthark Insights podcast looks to the future of innovation in the global health sector
Read more
Saudi firm Jameel Health in alliance with Evelo of US on COVID-19 therapeutic medicine
Gulf News reports Jameel Health and Evelo Biosciences form strategic alliance.
Read moreFor press inquiries click here, or call +971 4 448 0906 (GMT +4 hours UAE). For public inquiries click here.
